tbuckley/cabot-search huggingface dataset:
The Role of Microrna-196a-1 and Microrna-196b in Acute T-Lymphoblastic Leukemia and Acute Myeloid Leukemia.
Authors: Ebru Coskun, Eva Kristin von der Heide, Cornelia Schlee, Nicola Goekbuget, Dieter Hoelzer, Wolf-Karsten Hofmann, Eckhard Thiel, Claudia D Baldus
Journal: Blood (2009)
Unfavorable Prognostic Impact of MYC Increased Copy Number (ICN) in Patients with Diffuse Large B-Cell and High-Grade Lymphoma Treated with Immuno-Chemotherapy (ICT)
Authors: Francesca Schieppati, Simona Fisogni, Piera Balzarini, Alessandro Re, Luisa Lorenzi, Daniela Dalceggio, Angela Passi, Chiara Cattaneo, Fabio Facchetti, Giuseppe Rossi, Alessandra Tucci
Journal: Blood (2016)
MS4A3: A New Player in Leukemic Stem Cell Survival in Chronic Myeloid Leukemia
Authors: Anna M. Eiring, Jamshid S. Khorashad, Anupriya Agarwal, Clinton C. Mason, Russell Bell, Anna Senina, Anthony D. Pomicter, Fan Yu, Hannah M. Redwine, Amber D. Bowler, Phillip M. Clair, Srinivas K. Tantravahi, Shannon K. McWeeney, Brian J. Druker, Derek L. Stirewalt, Vivian Oehler, Thomas O'Hare, Michael W. Deininger
Journal: Blood (2016)
Hypomethylating Agents Correct Subcellular Localization of FOXO3a and (re)Establish Expression of Its Transcriptional Targets In AML and MDS- Cells
Authors: Sylvain Thepot, Elodie Lainey, Marie Sebert, Lionel Ades, Claude Gardin, Pierre Fenaux, Guido Kroemer, Simone Boehrer
Journal: Blood (2010)
Validity of Inclusion/Exclusion Criteria in Clinical Trials for Myelofibrosis and the Need for Expanded Access Programs [More Expanded Access Programs Are Needed to Assess the Impact of Comorbidity and Comedication in Patients with Myelofibrosis]
Authors: Susanne Isfort, Edgar Jost, Karla Bennemann, Martina Crysandt, Sema Akin, Tim H Brümmendorf, Steffen Koschmieder
Journal: Blood (2012)
Final Results of the ANAHYDRET-Study: Non-Inferiority of Anagrelide Compared to Hydroxyurea in Newly Diagnosed WHO-Essential Thrombocythemia Patients
Authors: Heinz Gisslinger, Mirjana Gotic, Jerzy Holowiecki, Miroslav Penka, Juergen Thiele, Hans Michael Kvasnicka, Robert Kralovics, Petro E. Petrides
Journal: Blood (2008)
Neoadjuvant chemotherapy with DD-MVAC and bevacizumab in high-risk urothelial cancer: Results from a phase II trial at the University of Texas M. D. Anderson Cancer Center.
Authors: Arlene O. Siefker-Radtke, Ashish M. Kamat, Paul G. Corn, Surena F. Matin, H. Barton Grossman, Randall E. Millikan, Colin P.N. Dinney
Journal: Journal of Clinical Oncology (2012)

4523 Background: DD-MVAC has shown an improved 5-year survival in metastatic urothelial cancer; however, there is no prospective data on its use in the neoadjuvant setting. Previous work suggested that over-expression of VEGF was associated with a high risk of relapse in our neoadjuvant patients, leading to the hypothesis that combining a VEGFR inhibitor with chemotherapy may improve patient outcomes. Methods: Between 8/07 and 12/10, 60 patients with urothelial carcinoma of the bladder or upper tract tumor were enrolled on a prospective phase II clinical trial. Eligibility requirements included at least one of the following: 3-D mass on EUA (cT3b disease), LVI, hydronephrosis, micropapillary features, tumor in a diverticula, and for upper tract tumors a high grade tumor or radiographically measurable sessile mass. The primary endpoint was pathologic down-staging to &lt;=pT1N0M0. Results: Forty-four patients with bladder/urethral tumors and 16 patients with upper tract tumors were enrolled. Pathologic down-staging to &lt;= pT1N0M0 occurred in 53% of patients overall (bladder/urethra 45%, upper tract 75%), and to &lt;= pT0N0M0 in 38% overall (bladder/urethra 39%, upper tract 38%). At a median follow-up of 26 months, the 2-year OS and DSS was 78% and 82%, respectively (bladder 2-yr OS and DSS 75%, 78%; upper tract 93%, 93%). The median OS and DSS have not yet been reached. The most common grade 3 or greater toxicity was neutropenia in 27% of patients, followed by fatigue in 10%. The following grade 3 toxicities were observed in &lt; 10% of patients: mucositis, DVT/PE, hypertension, nausea/vomiting, thrombocytopenia. One patient experienced cardiac ischemia. Conclusions: Neoadjuvant chemotherapy leads to pathologic down-staging in 45% of patients with bladder cancer. DD-MVAC appears an acceptable alternative to traditional M-VAC in the neoadjuvant setting. Although bevacizumab did not impact down-staging based upon historical expectations, determining the effect on recurrence requires longer follow-up.
Pharmacokinetics, pharmacodynamics, and tolerability of BCD-017, a novel pegylated filgrastim: Results of open-label controlled phase I study with dose escalation in healthy volunteers.
Authors: Kirill D. Nikitin, Sergei B. Fitilev, Tatiana V. Chernovskaya, Elena G. Rudenko, Alexander V. Vozzhaev, Yulia Y Titarova, Vadim A. Yakushev, Roman A. Ivanov
Journal: Journal of Clinical Oncology (2012)

9060 Background: Pegfilgrastim (conjugate of filgrastim and 20 kDa PEG) is approved for treatment of chemotherapy-associated neutropenia. BCD-017 is a covalent conjugate of filgrastim with 30 kDa PEG. Increased molecular weight of PEG molecule may provide additional benefits compared to pegfilgrastim. We have conducted this open-label phase I study to assess the PK, PD and tolerability of BCD-017. Methods: 24 healthy male volunteers signed the informed consent and were sequentially assigned to receive 1, 3 or 9 mg of BCD-017 or 5 mcg/kg/day of filgrastim for 7 days, 6 volunteers per group. Outcome measures included absolute neutrophil count (ANC) and СD34+ cell count, PK parameters and adverse events (AEs). Results: BCD-017 induced a fast and significant increase of ANC. Median maximum ANC (ANC max ) for BCD-017 1, 3, 9 mg and filgrastim was 18.68 (10.62-21.02), 25.92 (15.43-28.07), 32.22 (18.22-45.79), and 28.21 (21-31.95) ×10 3 cells/mm 3 , respectively; median time to ANC max was 24 (12-24); 48 (24-72); 72 (48-72); and 132,5 (12-169) h, respectively; median increase in СD34 + cells number 96 h post dose was 4.7 (1.2-6.5), 6.5 (1.7-12.3), 40.9 (24.5-102), and 17.8 (3.3-35.2) times, respectively. Filgrastim serum concentration was analyzed using ELISA. Median C max for BCD-017 3 and 9 mg and filgrastim was 45 (31-65), 446 (191-649), and 40 (20-54) ng/mL, respectively; median T max was 48 (24-72), 36 (24-48), and 8 (6-8) h respectively; median T 1/2 was 65 (51-70), 46 (41-57), and 6.7 (6.2-7.6) h, respectively. BCD-017 was well tolerated. No dose-limiting AEs were observed. AEs included headache, back pain, myalgia, arthralgia, thrombocytopenia, hyperuricemia, alkaline phosphatase/LDH increased. All AEs were of grade 1-2. Compared to filgrastim, the best tolerability was observed in 3 mg group. Conclusions: BCD-017 is shown to be a potent stimulator of granulopoiesis. BCD-017 3 mg did not differ from filgrastim in terms of ANC increase and its safety was shown in healthy volunteers. Further phase II study of BCD-017 for treatment and prophylaxis of neutropenia in patients receiving cytotoxic chemotherapy is necessary.
Interim Report of Phase II Study of Bortezomib Plus CHOP Every 2 Weeks in Patients with Disseminated Stage Diffuse Large B-Cell Lymphoma.
Authors: Jeong Eun Kim, Dae Ho Lee, Soon Il Lee, Jae Hoon Lee, Won Seog Kim, Bora Yoon, Cheolwon Suh
Journal: Blood (2009)
The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.
Authors: Gareth J. Morgan, David C. Johnson, John Crowley, John Shaughnessy, Pieter Sonneveld, Brian Durie, Christine Ramos, Brian G. Van Ness, Bart Barlogie, Antje Hoering, Jeff Haessler, Dalsu Baris, Michael Katz, Vincent S. Rajkumar, H. Goldschmidt
Journal: Blood (2006)
Trends in mortality related to pulmonary embolism in the European Region, 2000–15: analysis of vital registration data from the WHO Mortality Database
Authors: Stefano Barco, Seyed Hamidreza Mahmoudpour, Luca Valerio, Frederikus A Klok, Thomas Münzel, Saskia Middeldorp, Walter Ageno, Alexander T Cohen, Beverley J Hunt, Stavros V Konstantinides
Journal: The Lancet Respiratory Medicine (2019)
FLT3 Mutations in Normal Karyotype Acute Myeloid Leukemia in First Complete Remission Treated with Autologous Peripheral Blood Stem Cell Transplantation.
Authors: Goichi Yoshimoto, Koji Nagafuji, Toshihiro Miyamoto, Tetsuya Eto, Koji Kato, Shin Hayashi, Tomohiko Kamimura, Yuju Ohno, Shuichi Taniguchi, Mine Harada
Journal: Blood (2004)
Manufacturing an Enhanced CAR T Cell Product By Inhibition of the PI3K/Akt Pathway During T Cell Expansion Results in Improved In Vivo Efficacy of Anti-BCMA CAR T Cells
Authors: Molly R. Perkins, Shannon Grande, Amanda Hamel, Holly M. Horton, Tracy E. Garrett, Sara M. Miller, Howard J. Latimer, Christopher J. Horvath, Michael Kuczewski, Kevin M. Friedman, Richard A. Morgan
Journal: Blood (2015)
Final Results of Phase I/II Trial of the Oral mTOR Inhibitor Everolimus (RAD001) in Combination with Bortezomib and Rituximab (RVR) in Relapsed or Refractory Waldenstrom Macroglobulinemia
Authors: Irene M. Ghobrial, Robert Allyn Redd, Jeffrey Matous, Philippe Armand, Erica N Boswell, Stacey Chuma, Kimberly Noonan, Megan H. MacNabb, Ranjit Banwait, Courtney Hanlon, Houry Leblebjian, Diane Warren, Jorge J. Castillo, Jacob P. Laubach, Claudia E. Paba-Prada, Kenneth C. Anderson, Paul G. Richardson, Edie A. Weller, Steven P Treon
Journal: Blood (2014)
Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC-CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT)
Authors: Simona Pagliuca, Régis Peffault de Latour, Franco Locatelli, Jean-Hugues Dalle, Kim Vettenranta, Miguel Angel Diaz, Or Reuven, Cristina Diaz de Heredia, Arnon Nagler, Ardeshir Ghavamzadeh, Sabina Sufliarska, Sarah Lawson, Chantal Kenzey, Vanderson Rocha, Carlo Dufour, Eliane Gluckman, Jakob Passweg, Annalisa Ruggeri
Journal: Blood (2015)
Upregulation of Tissue Factor in Polymorphonuclear Leukocytes from Patients with Myeloproliferative Disorders and Inhibition by Hydroxyurea Treatment.
Authors: Norma Maugeri, Chiara Cerletti, Giulio Giordano, Maria P. Petrilli, Vincenzo Fraticelli, Giovanni de Gaetano, Giuseppe Leone, Sergio Storti, Maria B. Donati
Journal: Blood (2006)
Awareness Towards Breast and Cervical Cancer Risk factors and its prevention among students and patients in Bangladesh
Authors: Md Shariful Islam, Farzana Sultana, A.K.M. Nazrul Islam, Nur-E- Alam, Hedayet Ullah, tarek Molla, Mst Mahmuda Khatun, A.K.M. Mohiuddin
Journal: Annals of Oncology (2019)
Superior PFS2 with VTD Vs TD for Newly Diagnosed, Transplant Eligible, Multiple Myeloma (MM) Patients: Updated Analysis of Gimema MMY-3006 Study
Authors: Paola Tacchetti, Lucia Pantani, Valerio De Stefano, Elena Zamagni, Jacopo Peccatori, Annalisa Pezzi, Catello Califano, Andrea Nozza, Patrizia Tosi, Carolina Terragna, Fabrizio Ciambelli, Delia Cangini, Piero Galieni, Clotilde Cangialosi, Giovanni De Sabbata, Francesca Elice, Antonio Palumbo, Michele Cavo
Journal: Blood (2014)
The Common Genomic Locus of Evl and MiR-342 Regulates Both Lymphopoiesis and Myelopoiesis
Authors: Tonio Lang, Friederike Herbst, Elias Eckert, Peer Wünsche, Shayda Hemmati, Tim Kindinger, Nina Hofmann, Oksana Zavidij, Manfred Schmidt, Claudia Ball, Hanno Glimm
Journal: Blood (2015)
L-Asparaginase More Effectively Targets Leukemic Cells with Low Glycolytic Activity
Authors: Simcikova Marketa, Alena Pecinova, Ivana Hermanova, David Pajuelo Reguera, Katerina Rejlova, Marketa Zaliova, Jan Stuchly, Tomas Mracek, Jan Trka, Julia Starkova
Journal: Blood (2015)
Exploring the lived experience of a high grade glioma
Authors: Shivani Soni, Matthew Williamas, Antonia Lannie
Journal: Neuro-Oncology (2019)

Abstract Introduction Brain tumour patients face a variety of challenges during diagnosis and treatment. Although most treating clinicians are familiar with these, it can be difficult to obtain a comprehensive overview of which are the most common problems, which patients they affect and how to address them. Methods We conducted a systematic review of all work relating to the lived experience of patients and carers of a glioblastoma. We identified articles published between 2008 and 2018 these had to be published in English, using the search terms cares and patients, lived experience, glioblastoma and perspective with relative alternative terms. We excluded articles that were previous systematic reviews, included low grade/brain metastasis from another primary site and articles that combined results for patients and carers. We extracted key theme and concerns, and summarised and tabulated and developed a discussion/recommendation. Results We identified 405 potential studies. We rejected 374 after screening abstract and titles, and a further 23 on further review. This left a set of 8 unique publications. The 8 publications included were comprised of qualitative studies that explored patient and carers experience at different points in the patient pathway. The main concerns/themes identified were issues around communication specifically the shock of diagnosis, re-negotiating relationships and finally accessing support. Conclusions This is the first systematic review that collates the lived experience of patients with high grade gliomas. It differs from the palliative care literature and from the James Lind Alliance, and is more specific than generic health needs assessments that are being used in practice.
Fluoropyrimidine-based chemotherapy for gastrointestinal cancer in patients with direct oral anticoagulants or warfarin
Authors: Yuki Matsubara, Takayuki Ando, Miho Sakumura, Hiroki Yoshita, Sohachi Nanjo, Hiroshi Mihara, Haruka Fujinami, Kenichiro Tsukada, Kajiura Shinya, Kohei Ogawa, Ayumu Hosokawa, Mitsuhiro Terada, Ichiro Yasuda
Journal: Annals of Oncology (2019)
Genetic Polymorphisms Correlated with Outcome in Multiple Myeloma Patients Receiving High Dose Melphalan.
Authors: Charles Dumontet, Stefano Landi, Tony Reiman, Adriana Plesa, Ilaria Bellini, Roberto Barale, Linda M. Pilarski, Sean Tavtigian, Troy Perry, Federica Gemignani
Journal: Blood (2007)
Quantitative Multiplexed Immunohistochemistry Assays for Exploring CAR Modified T Cells and Checkpoint Inhibitors in Lymphoma Trials
Authors: Thai Hong Tran, Krupa Scott, Shyun-Shyun Lee, Reshma Singh, Shawn Cogan, Jennifer Bordeaux, Hummel Jennifer, Jelveh Lameh, Catherine Tribouley, Sadik Kassim, Shabnam Tangri, Naveen Dakappagari
Journal: Blood (2015)
ABC Proteins Activity Remains An Independent Prognostic Factor In 206 AML When Compared to Other Molecular Markers, FLT3, NPM1, CEBPα, and BAALC
Authors: Pierre Hirsch, Ruoping Tang, Christophe Marzac, Jean-Yves Perrot, Fanny Fava, Chantal Bernard, Jean-Pierre Marie, Ollivier Legrand
Journal: Blood (2010)
Frequent but Reversible and Manageable Cardiac Complications after Successful Haploidentical HLA-Mismatched Hematopoietic Stem Cell Transplantation (HSCT) without Ex Vivo Graft Manipulation.
Authors: Kumi Oshima, Yoshinobu Kanda, Mamiko Sakata-Yanagimoto, Yuki Asano-Mori, Koji Izutsu, Seishi Ogawa, Toru Motokura, Shigeru Chiba, Hisamaru Hirai
Journal: Blood (2004)
Clinical Impact of the Presence of a Diffuse Large B-Cell Lymphoma (DLBCL) Component in the Outcome of Untreated Patients with Follicular Lymphoma (FL)
Authors: Laura Magnano, Ivan Dlouhy, Olga Balagué, Alfredo Rivas-Delgado, Jordina Rovira, Kennosuke Karube, Blanca Gonzalez, Alejandra Martinez-Trillos, Antonio Martínez, Julio Delgado, Eva Gine, Neus Villamor, Elias Campo, Armando Lopez-Guillermo
Journal: Blood (2016)
Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR4.5. Preliminary Results of a Phase II Study.
Authors: Franck E. Nicolini, Gabriel Etienne, Viviane Dubruille, Lydia Roy, Françoise Huguet, Laurence Legros, Stephane Giraudier, Valérie Coiteux, Agnès Guerci-Bresler, Pascal Lenain, Delphine Rea, Shanti Ame, Pascale Cony-Makhoul, Martine Gardembas, Eric Hermet, Philippe Rousselot, Marie-Claude Gagnieu, Stephane Morisset, Christine Pivot, Madeleine Etienne, François Guilhot, Stephanie Dulucq, Francois-Xavier Mahon
Journal: Blood (2012)
Update: Influenza Activity — United States and Worldwide, May 19–September 28, 2019, and Composition of the 2020 Southern Hemisphere Influenza Vaccine
Authors: Scott Epperson, C. Todd Davis, Lynnette Brammer, Anwar Isa Abd Elal, Noreen Ajayi, John Barnes, Alicia P. Budd, Erin Burns, Peter Daly, Vivien G. Dugan, Alicia M. Fry, Yunho Jang, Sara Jo Johnson, Krista Kniss, Rebecca Kondor, Lisa A. Grohskopf, Larisa Gubareva, Angiezel Merced-Morales, Wendy Sessions, James Stevens, David E. Wentworth, Xiyan Xu, Daniel Jernigan
Journal: MMWR Morbidity and Mortality Weekly Report (2019)

During May 19-September 28, 2019,* low levels of influenza activity were reported in the United States, with cocirculation of influenza A and influenza B viruses. In the Southern Hemisphere seasonal influenza viruses circulated widely, with influenza A(H3) predominating in many regions; however, influenza A(H1N1)pdm09 and influenza B viruses were predominant in some countries. In late September, the World Health Organization (WHO) recommended components for the 2020 Southern Hemisphere influenza vaccine and included an update to the A(H3N2) and B/Victoria-lineage components. Annual influenza vaccination is the best means for preventing influenza illness and its complications, and vaccination before influenza activity increases is optimal. Health care providers should recommend vaccination for all persons aged ≥6 months who do not have contraindications to vaccination (1).
Cidofovir Is a Highly Effective and Safe Salvage Therapy in Ganciclovir Resistant Cytomegalovirus Reactivation Following Allogeneic Haematopoietic Stem Cell Transplantation
Authors: David Lewis, Francesca Farina, Sandeep Nagra, Sridhar Chaganti, Annette Pachnio, Jane Nunnick, Paul AH Moss, Ram Malladi, Charles F. Craddock
Journal: Blood (2012)
Impact of Donor-Derived Invariant Natural Killer T (iNKT) Cell Reconstitution After Allogeneic Haematopoietic Stem Cell Transplantation.
Authors: Marie T Rubio, Lucia Teixeira, Pierre Milpied, Emmanuel Bachy, Felipe Suarez, David Ghez, Richard Delarue, Agnès Buzyn, Sophie Caillat-Zucman, Bruno Varet, Olivier Hermine, Maria Leite de Moraes
Journal: Blood (2009)
Phase 2 Study of Intramyocardial Injection of Autologous CD34+ Cells to Treat Subjects with Refractory Chronic Myocardial Ischemia (CMI): Factors Influencing Mobilization and Apheresis.
Authors: Deborah Livingston, Delara Motlagh, Joan Debelak, Amy Cohen, Kenneth Story, Suzann Hammel, Alamdar Rizvi, Jodi Brennan Kunzik, Peter X Adams, Timothy Henry, Douglas W Losordo, David Amrani
Journal: Blood (2009)
Noninvasive Assessment of Intestinal Graft-Versus-Host Disease Activity by 18F-Fluorodeoxyglucose Positron Emission Tomography.
Authors: Matthias Stelljes, Jorn Albring, Sven Hermann, Christopher Poremba, Gabiele Kohler, Christoph Bremer, Thorsten Kucharzik, Gerda Silling, Wolfgang E. Berdel, Otmar Schober, Michael Schafers, Joachim Kienast
Journal: Blood (2006)
p15INK4b Methylation Is Related to Blast Percentage, Thrombocytopenia, the Number of Lineages Involved in Cytopenia and Survival in Myelodysplastic Syndrome at the Time of Diagnosis: a Pyrosequencing Study.
Authors: Miyoung Kim, Bora Oh, Song-yee Kim, Hyun-Kyung Park, Sang Mee Hwang, Hee Won Moon, Cha Ja She, Inchul Yang, Sung-Soo Yoon, Jong Hyun Yoon, Dong Soon Lee
Journal: Blood (2009)
Autologous Stem Cell Transplantation (ASCT) in Multiple Myeloma (MM) Patients with Dialysis-Dependent Renal Failure Is Effective but Carries High Rates of Toxicity.
Authors: Lisa Chodirker, Joseph R. Mikhael, Keith Stewart, Andrew Winter, Donna E. Reece, Norman Franke, Suzanne Trudel, Vishal Kukreti, Wei Xu, Christine I. Chen
Journal: Blood (2007)
Use of G-CSF in Patients with Severe Aplastic Anemia Treated with ATG and Cyclosporine Increases Neutrophils and Decreases Infection Rates and Hospitalization Days but Does Not Improve Long-Term Outcome: Results of a Prospective, Randomized Clinical Trial of the EBMT.
Authors: AndrÉ Tichelli, Hubert Schrezenmeier, Gerard Socié, Judith Marsh, Andrea Bacigalupo, Ulrich Duehrsen, Anke Franzke, Michael Hallek, Eckhard Thiel, Martin Wilhelm, Britta Höchsmann, Alain Barrois, Kim Champion, Jakob R. Passweg
Journal: Blood (2009)
High-Vorticity with Periodic Flow Enhances in Vitro Biogenesis of Healthy Platelets from iPSC-Derived-Megakaryocytes
Authors: Yukitaka Ito, Sou Nakamura, Tomohiro Shigemori, Naoshi Sugimoto, Yoshikazu Kato, Kazuya Hashimoto, Naohide Watanabe, Masayuki Nogawa, Makoto Handa, Satoshi Nishimura, Koji Eto
Journal: Blood (2016)
Experience with 2 Dose Schedules of Inotuzumab Ozogamicin, Single Dose, and Weekly, in Refractory-Relapsed Acute Lymphocytic Leukemia (ALL)
Authors: Susan O'Brien, Deborah A. Thomas, Jeffrey L. Jorgensen, Partow Kebriaei, Farhad Ravandi, Monica Kwari, Stefan Faderl, Jorge E. Cortes, Elias J. Jabbour, Sergernne York, Rebecca Garris, Hagop M. Kantarjian
Journal: Blood (2012)
North American Cooperative Group Members' Patterns of Blood Products Transfusion for Patients with Acute Leukemia
Authors: Alexander B Pine, Eun-Ju Lee, Mikkael A. Sekeres, David P. Steensma, Thomas Prebet, Amy E. DeZern, Rami S. Komrokji, Mark R Litzow, Selina Luger, Richard M. Stone, Harry P Erba, Guillermo Garcia-Manero, Alfred I Lee, Nikolai A. Podoltsev, Lisa Barbarotta, Jeanne E. Hendrickson, Steven D. Gore, Amer M. Zeidan
Journal: Blood (2015)
Risk of Central Nervous System (CNS) Involvement in Patients with Mantle Cell Lymphoma (MCL): Analysis of Clinico-Biological Factors in a Series of 283 Cases
Authors: Eva Giné, Sílvia Beà, Alba Navarro, Nuria Martínez-Cibrián, Itziar Salaverría, David Martín-García, Pedro Jares, Magda Pinyol, Cristina Royo, Guillem Clot, Marta Aymerich, Neus Villamor, Lluis Colomo, Antonio Martínez, Alexandra Valera, María Rozman, Anna Enjuanes, Pilar Forcada, Anna Muntanola, Elena Hartmann, Andreas Rosenwald, German Ott, Marcos González, Jesús M Hernández-Rivas, Wolfram Klapper, Reiner Siebert, Adrian Wiestner, Wyndham H. Wilson, Maria José Calasanz, Laura Magnano, Jordina Rovira, Dolors Colomer, Elias Campo, Armando Lopez-Guillermo
Journal: Blood (2014)
Allele-Specific Crispr Targeting Reveals Epigenetic and Phenotypic Effects of a MMSET Gain of Function Mutation Found in Relapsed Acute Lymphoblastic Leukemia
Authors: Jon Oyer, Christine Will, Xiaoxiao Huang, Teresa Ezponda, Relja Popovic, Yupeng Zheng, Neil L Kelleher, Jonathan D. Licht
Journal: Blood (2015)